Dr Colleen Delaney | Chief Medical Officer
Nohla Therapeutics

Dr Colleen Delaney, Chief Medical Officer, Nohla Therapeutics

Dr. Colleen Delaney is a Founder and the Chief Medical Officer of Nohla Therapeutics, Inc., a cellular therapy company focused on developing off-the-shelf, universal-donor therapies that require no HLA matching. 

Dr. Delaney’s research interests focus on the role of the Notch signaling pathway in hematopoietic stem cell regulation and ex-vivo expansion of umbilical cord blood stem and progenitor cells for clinical applications. Her group has developed a novel and clinically feasible method for the ex vivo expansion of cord blood derived hematopoietic stem and progenitor cells in the presence of Notch ligands. This work was translated into a novel pilot study investigating the use of ex vivo expanded cord blood progenitors to augment conventional cord blood transplantation. She has since extended this work to investigate the potential of cryopreserved, non-HLA matched “off the shelf” ex vivo expanded cord blood progenitor cells to provide rapid but transient myeloid reconstitution in the setting of cord blood transplant and following dose-intensive chemotherapy.

Dr. Delaney is a Member and the Madeline Dabney Adams Endowed Chair in AML Research of the Fred Hutchinson Cancer Research Center Clinical Research Division, and an Associate Professor at the University of Washington in the Department of Pediatrics, Division of Pediatric Hematology/Oncology. She is an attending physician at Seattle Children’s Hospital and the Seattle Cancer Care Alliance, and she established and directs the Cord Blood Transplant Program at Fred Hutch/SCCA. 

She is the recipient of several prestigious awards, including the Damon Runyon Clinical Investigator Award, Seattle Top Doctor Award 2011/2012, the Dr. Ali Al-Johani Award in recognition of exemplary clinical medical care and compassion to patients and families in 2013, and the 2016 Leaders in Health Care: Outstanding Medical Research Award from Seattle Business Magazine. She also serves on the Board of Directors for ASBMT, is a founding member and on the Board of Directors for the Cord Blood Association, and is a standing NIH grant review committee member.

She holds a bachelor’s degree in Molecular Biology and Biochemistry from Wesleyan University, a MSc in Social Research and Social Policy from Oxford University, and a M.D. from Harvard Medical School. Colleen did her residency in General Pediatrics at the University of California, San Francisco and a Fellowship in Pediatric Hematology/Oncology at Fred Hutchinson Cancer Research Center/ Seattle Children’s Hospital and Regional Medical Center. 


Cord Blood Day 2- Thursday 17th May 2018 @ 09:00

Universal donor ex vivo expanded hematopoietic progenitor cells for clinical application: to the Neutrophil and Beyond

  • Ex vivo expansion in human hematopoietic stem cells
  • Bench to bedside translation and development of a universal donor product
  • Clinical application of universal donor stem cell product in stem cell transplant and chemo induced neutropenia

Cord Blood Day 2- Thursday 17th May 2018 @ 11:40

Panel Discussion: collaborative cord blood banking

  •     Why aren't all private and public blood banks joining the CBA?
  •     Tackling lack of communication between researchers, biobanks and regulators
  •     How to increase international circulation of cord units  

back to speakers



Erica Baeta
+44 (0)207 092 1152


Jessica Robinson
t/ +44 (0)207 092 1150


Issa Mauthoor
+44 (0)207 092 1257